Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
1.26
Dollar change
-0.07
Percentage change
-5.26
%
Index- P/E- EPS (ttm)-44.53 Insider Own- Shs Outstand- Perf Week4.13%
Market Cap0.86M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month17.76%
Income-1.80M PEG- EPS next Q- Inst Own11.38% Short Float- Perf Quarter-82.88%
Sales3.35M P/S0.26 EPS this Y- Inst Trans1.06% Short Ratio0.25 Perf Half Y-88.75%
Book/sh0.01 P/B98.28 EPS next Y- ROA-13.34% Short Interest0.21M Perf Year-98.44%
Cash/sh3.59 P/C0.35 EPS next 5Y- ROE-94.90% 52W Range0.85 - 88.00 Perf YTD-60.25%
Dividend Est.- P/FCF- EPS past 5Y- ROI-38.53% 52W High-98.57% Beta0.26
Dividend TTM- Quick Ratio1.09 Sales past 5Y13.10% Gross Margin- 52W Low48.22% ATR (14)0.24
Dividend Ex-Date- Current Ratio1.09 EPS Y/Y TTM- Oper. Margin-416.80% RSI (14)44.69 Volatility10.32% 17.11%
Employees77 Debt/Eq1.16 Sales Y/Y TTM- Profit Margin-53.62% Recom1.00 Target Price138.50
Option/ShortNo / No LT Debt/Eq0.83 EPS Q/Q- Payout- Rel Volume0.25 Prev Close1.33
Sales Surprise- EPS Surprise- Sales Q/Q2.07% Earnings- Avg Volume815.76K Price1.26
SMA2010.73% SMA50-28.97% SMA200-84.40% Trades Volume200,951 Change-5.26%
Mar-01-24 08:30AM
Feb-27-24 05:15PM
Feb-22-24 09:32AM
Feb-15-24 08:30AM
Feb-14-24 08:30AM
08:30AM Loading…
Jan-29-24 08:30AM
Jan-18-24 08:30AM
Jan-04-24 08:30AM
Jan-03-24 08:30AM
Dec-22-23 08:30AM
Dec-19-23 08:00AM
Dec-18-23 11:15AM
Dec-13-23 06:30AM
Nov-28-23 11:05AM
Nov-27-23 08:45AM
10:00AM Loading…
Nov-14-23 10:00AM
Nov-02-23 01:30PM
Oct-25-23 08:00AM
Oct-24-23 08:45AM
Oct-23-23 08:00AM
Sep-27-23 08:00AM
Sep-05-23 08:30AM
Aug-29-23 08:30AM
Jul-31-23 08:30AM
Jul-06-23 09:08AM
May-24-23 09:00AM
May-04-23 06:29AM
Apr-26-23 08:30AM
Apr-19-23 08:00AM
Mar-30-23 04:15PM
08:05AM Loading…
Mar-28-23 08:05AM
Mar-22-23 08:30AM
Mar-16-23 12:00PM
Mar-07-23 08:30AM
Feb-23-23 08:30AM
Feb-21-23 08:30AM
Feb-14-23 08:30AM
Feb-13-23 04:15PM
Feb-07-23 08:30AM
Jan-30-23 08:30AM
Jan-20-23 08:30AM
Jan-19-23 08:30AM
Jan-17-23 08:30AM
Jan-12-23 06:50AM
Dec-12-22 09:00AM
Nov-30-22 06:43PM
Nov-28-22 08:00AM
Nov-22-22 08:00AM
Nov-21-22 05:55AM
Oct-26-22 08:30AM
Oct-03-22 08:30AM
Sep-13-22 09:30AM
Aug-22-22 08:30AM
Jul-25-22 08:30AM
Jul-08-22 08:30AM
Jun-07-22 04:00PM
Jun-02-22 06:10PM
May-31-22 10:00AM
May-23-22 08:30AM
May-18-22 08:30AM
May-03-22 08:30AM
Apr-26-22 08:45AM
Apr-21-22 08:00AM
Apr-06-22 10:03AM
08:30AM
Mar-29-22 08:30AM
Mar-23-22 08:30AM
Mar-17-22 08:30AM
Mar-15-22 08:30AM
Mar-08-22 08:30AM
Mar-02-22 08:30AM
Feb-22-22 08:30AM
Feb-15-22 05:08PM
Feb-11-22 09:31AM
Feb-10-22 10:01PM
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.